{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:31:52Z","timestamp":1783020712852,"version":"3.54.6"},"reference-count":64,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The therapeutic landscape of follicular lymphoma (FL) is undergoing a transformative shift driven by the advent of novel chemo\u2010free strategies that challenge the traditional chemo\u2010oriented paradigms; this shift offers promising alternatives for both newly diagnosed and relapsed or refractory (RR) patients. Available data support a full chemo\u2010free approach starting from second\u2010line therapy, with rituximab\u2013lenalidomide (R2) or tafasitamab\u2010R2, whereas bispecific antibodies (bsAbs), Bruton's tyrosine kinase (BTK) inhibitors and chimeric antigen receptor (CAR) T\u2010cell therapies are available options after second relapse. In the near future, bsAbs, mainly in combination with lenalidomide, will likely be employed as first\u2010 or second\u2010line therapy, potentially fully replacing immunochemotherapy, whereas CAR T\u2010cell therapy will play a role in selected high\u2010risk patients. Given the different toxicity profiles of chemo\u2010free options, refined prognostic scores are awaited so as to properly allocate patients to the most appropriate therapy with the best trade\u2010off between efficacy and safety.<\/jats:p>","DOI":"10.1111\/bjh.70126","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T10:50:35Z","timestamp":1756551035000},"page":"1755-1764","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Towards a chemo\u2010free approach for follicular lymphoma"],"prefix":"10.1111","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"first","affiliation":[{"name":"Division of Hematology Azienda Unit\u00e0 Sanitaria Locale \u2010 IRCCS  Reggio Emilia Italy"},{"name":"CHIMOMO Department University of Modena and Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Division of Hematology Azienda Unit\u00e0 Sanitaria Locale \u2010 IRCCS  Reggio Emilia Italy"},{"name":"Clinical and Experimental Medicine Doctorate School University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-6788","authenticated-orcid":false,"given":"Maria Elena","family":"Nizzoli","sequence":"additional","affiliation":[{"name":"Division of Hematology Azienda Unit\u00e0 Sanitaria Locale \u2010 IRCCS  Reggio Emilia Italy"},{"name":"Clinical and Experimental Medicine Doctorate School University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00067"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000258"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000662"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx189"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3184"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.025"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1652"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(25)00034\u20101"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002858"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00262"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00843"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158631"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145640"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4"},{"issue":"2","key":"e_1_2_9_31_1","first-page":"439","article-title":"Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non\u2010Hodgkin lymphoma: real\u2010life experience","volume":"110","author":"Cassanello G","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174901"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010212970"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19951"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"issue":"23","key":"e_1_2_9_37_1","first-page":"2628","article-title":"Venetoclax\u2010rituximab with or without bendamustine vs bendamustine\u2010rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani PL","year":"2020","journal-title":"Blood"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28229"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179910"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00345\u20104"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010193589"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00166\u20102"},{"issue":"3","key":"e_1_2_9_47_1","first-page":"e5547136","article-title":"S222: epcoritamab with rituximab + lenalidomide (R2) provides durable responses in patients with high\u2010risk follicular lymphoma, regardless of POD24 status","volume":"7","author":"Sureda A","year":"2023","journal-title":"Hema"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"issue":"1","key":"e_1_2_9_49_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-136834","article-title":"Primary analysis of Zuma\u20105: a phase 2 study of axicabtagene ciloleucel (Axi\u2010Cel) in patients with relapsed\/refractory (R\/R) indolent non\u2010Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson C","year":"2020","journal-title":"Blood"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3164_271"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_138"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002986\u20109"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010174914"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184653"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14157"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184883"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000667"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010182244"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S509907"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02329"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01562-3"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010205046"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:07:59Z","timestamp":1783015679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/bjh.70126"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70126","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"2025-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}